- Trials with a EudraCT protocol (37)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3,005)
37 result(s) found for: BAC.
Displaying page 1 of 2.
EudraCT Number: 2013-000663-83 | Sponsor Protocol Number: SM3-ME-13 | Start Date*: 2013-04-19 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: The effect of Adductor-Channel Blockade with high pain responders after reconstruction of the anterior cruciate ligament | |||||||||||||
Medical condition: Patients who will undergo reconstruktion of ligament cruciate ligament. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002915-24 | Sponsor Protocol Number: 0178 | Start Date*: 2019-10-24 | |||||||||||
Sponsor Name:Theravance Biopharma Ireland Limited | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study to Evaluate the Effects of Repeated Doses of Inhaled TD-8236 and Impact on Airway Responses Following Allergen Challenge in ... | |||||||||||||
Medical condition: Treatment of airway inflammation, initially in asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004648-29 | Sponsor Protocol Number: C05002 | Start Date*: 2005-05-09 |
Sponsor Name:Janssen Cilag International, N.V. (Sponsor in European Union) | ||
Full Title: A Multicenter, Open-label, Phase 2 Study of VELCADE (bortezomib) for Injection in Previously Treated Patients with Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloa... | ||
Medical condition: Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveolar Features | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-004628-31 | Sponsor Protocol Number: FIL_V-RBAC | Start Date*: 2018-05-15 | |||||||||||
Sponsor Name:Fondazione Italiana Linfomi ONLUS | |||||||||||||
Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) | |||||||||||||
Medical condition: Mantle Cell Lymphoma in elderly patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001027-13 | Sponsor Protocol Number: SELK2-00006 | Start Date*: 2020-06-29 | ||||||||||||||||
Sponsor Name:Tetherex Pharmaceuticals Corporation | ||||||||||||||||||
Full Title: A Two Part, Randomised, Double-blind, Placebo-controlled, Phase 2 Parallel Group Study to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 on Airway Responses Following Allergen... | ||||||||||||||||||
Medical condition: Part 1: Asthma Part 2: Chronic Obstructive Pulmonary Disease (COPD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000564-29 | Sponsor Protocol Number: SUGBG-013001 | Start Date*: 2013-04-25 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases | ||
Medical condition: Uveal melanoma liver metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000618-32 | Sponsor Protocol Number: GNC-501 | Start Date*: 2022-09-29 | ||||||||||||||||
Sponsor Name:GENEURO SA | ||||||||||||||||||
Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy... | ||||||||||||||||||
Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023627-14 | Sponsor Protocol Number: 201052 | Start Date*: 2011-02-09 | ||||||||||||||||
Sponsor Name:Santen Oy | ||||||||||||||||||
Full Title: Cross-sectional study to investigate the occurence and severity of signs and symptoms of ocular surface disease in patients with ongoing chronic topical treatment for glaucoma or ocular hypertension. | ||||||||||||||||||
Medical condition: Glaucoma or ocular hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005479-17 | Sponsor Protocol Number: 400-11-002 | Start Date*: 2012-05-02 |
Sponsor Name:Ethicon Inc., a Johnson & Johnson Co. | ||
Full Title: A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques | ||
Medical condition: Gastrointestinal Anastomosis Leak | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005739-23 | Sponsor Protocol Number: FIL-RBAC500 | Start Date*: 2012-03-06 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Phase II study of age‐adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL) | |||||||||||||
Medical condition: Patients with an established histological diagnosis of MCL on lymph‐node biopsy, bone marrow biopsy, or extranodal tissue. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002507-28 | Sponsor Protocol Number: OPHT-280515 | Start Date*: 2015-07-20 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Effect of benzalkonium chloride containing eye drops on the conjunctival bacterial flora of dry eye patients. | |||||||||||||
Medical condition: conjunctival bacterial flora in patients with dry eye syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001178-70 | Sponsor Protocol Number: BECRO/ACT/ORASIS-LT | Start Date*: 2023-01-26 | |||||||||||||||||||||
Sponsor Name:actrevo GmbH | |||||||||||||||||||||||
Full Title: Non-inferiority, Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic BAC-free Formulation of Latanoprost/Timolol 0.05 mg/mL +... | |||||||||||||||||||||||
Medical condition: Open angle glaucoma or ocular hypertension | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000417-44 | Sponsor Protocol Number: PHP-OCM-301A | Start Date*: 2016-03-31 | |||||||||||
Sponsor Name:Delcath Systems, Inc | |||||||||||||
Full Title: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma. | |||||||||||||
Medical condition: Hepatic-Dominant Ocular Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004307-14 | Sponsor Protocol Number: BECRO/ACT/LATANOS | Start Date*: 2021-02-12 | ||||||||||||||||
Sponsor Name:actrevo GmbH | ||||||||||||||||||
Full Title: Non-inferiority, Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic BAC-free Formulation of Latanoprost 0.05 mg/mL eye drops... | ||||||||||||||||||
Medical condition: Open angle glaucoma or ocular hypertension Elevated IOP and paediatric glaucoma. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003834-34 | Sponsor Protocol Number: NBI-1065844-CIAS2023 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop... | |||||||||||||
Medical condition: Cognitive Impairment Associated With Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001264-37 | Sponsor Protocol Number: 1200.40 | Start Date*: 2008-11-20 | |||||||||||
Sponsor Name:BOEHRINGER ING. | |||||||||||||
Full Title: A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients | |||||||||||||
Medical condition: Patients affected by NSCLC EGFR FISH positive. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002334-11 | Sponsor Protocol Number: 12014A | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Nalmefene Efficacy Study I: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence | |||||||||||||
Medical condition: Alcohol dependence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) FI (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002831-16 | Sponsor Protocol Number: TUD-TEMANX-065 | Start Date*: 2015-10-20 | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: Validation of a test system for development of medications for alcoholism | |||||||||||||
Medical condition: male and female volunteers aged 25-55 years with moderate risky alcohol consumption of at least 41 g/day (men) or 31 g/day (women), according to European Medicines Agency (EMA, 2010) this is at lea... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000207-90 | Sponsor Protocol Number: P15-14/BF2.649 | Start Date*: 2016-11-24 | |||||||||||
Sponsor Name:BIPROJET PHARMA | |||||||||||||
Full Title: A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment. | |||||||||||||
Medical condition: Patients with moderate to severe alcohol use disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004973-42 | Sponsor Protocol Number: 1289.32 | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter... | |||||||||||||
Medical condition: attenuated psychosis syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
